NCT01535573

Citalopram for Cocaine Dependence

Clinical Trial of Serotonin Medication Combination in Cocaine Dependence

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 108 (actual)
• Sponsor: Joy Schmitz · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 2 clinical trial of citalopram pharmacotherapy for treatment of cocaine dependence. Using a double-blind, randomized controlled design, eligible cocaine dependent patients will be assigned equally to one of three medication conditions: placebo or the Selective serotonin re-uptake inhibitor (SSRI) agent, citalopram at either 20 mg per day or 40 mg per day. It is hypothesized that citalopram will reduce cocaine use and increase periods of sustained abstinence substantially more than placebo. Performance on a set of behavioral tasks of impulsivity will be analyzed as potential predictors of treatment response.

Conditions

• Cocaine Dependence

Interventions

Type	Name	Description
DRUG	Citalopram	20 mg once per day for 9 weeks
DRUG	Citalopram	40 mg per day for 9 weeks
DRUG	Placebo	0 mg per day for 9 weeks

Timeline

• Start date: 2010-12-01
• Primary completion: 2016-07-01
• Completion: 2016-07-01
• First posted: 2012-02-17
• Last updated: 2020-09-16
• Results posted: 2020-08-31

Locations

1 site across 1 country: United States